Rik Ossenkoppele

Oct 12, 2024 | alzres.biomedcentral.com | Anna Svenningsson |Diana I. Bocancea |Erik Stomrud |Frederik Barkhof |Niklas Mattsson-Carlgren |Sebastian Palmqvist | +3 more

Sep 14, 2024 | nature.com | Lyduine E. Collij |Ruben Smith |Sebastian Palmqvist |Rik Ossenkoppele

AbstractIdentifying concomitant Lewy body (LB) pathology through seed amplification assays (SAA) might enhance the diagnostic and prognostic work-up of Alzheimer’s disease (AD) in clinical practice and trials. This study examined whether LB pathology exacerbates AD-related disease progression in 795 cognitively impaired individuals (Mild Cognitive Impairment and dementia) from the longitudinal multi-center observational ADNI cohort.

Jun 14, 2024 | nature.com | Sophie E Mastenbroek |Jacob Vogel |Lyduine E. Collij |Alexandra Young |Frederik Barkhof |Rik Ossenkoppele

AbstractLewy body (LB) diseases, characterized by the aggregation of misfolded α-synuclein proteins, exhibit notable clinical heterogeneity. This may be due to variations in accumulation patterns of LB neuropathology. Here we apply a data-driven disease progression model to regional neuropathological LB density scores from 814 brain donors with Lewy pathology.

Jun 13, 2024 | medrxiv.org | Rik Ossenkoppele |Gemma Salvadó |Shorena Janelidze |Alexa Pichet Binette

R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics. He has given lectures in symposia sponsored by GE Healthcare and serves on advisory boards for Asceneuron and Bristol Myers Squibb. SP has acquired research support (for the institution) from ki elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Lilly, and Roche.

Apr 29, 2024 | jamanetwork.com | Rik Ossenkoppele |Vrije Universiteit Amsterdam |Amsterdam Neuroscience |Charlotte Teunissen

Fluid Biomarker Changes After Amyloid-β–Targeting Drugs Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease Olivia Wagemann, MD; Haiyan Liu, MD; Guoqiao Wang, PhD; Xinyu Shi, MS; Tobias Bittner, PhD; Marzia A. Scelsi, PhD; Martin R. Farlow, MD; David B. Clifford, MD; Charlene Supnet-Bell, PhD; Anna M. Santacruz, BS; Andrew J. Aschenbrenner, PhD; Jason J. Hassenstab, PhD; Tammie L. S. Benzinger, MD, PhD; Brian A.